


PRODUCT INFORMATION



GW 842166X

Item No. 10010372

CAS Registry No.: 666260-75-9
Formal Name: 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)-5-pyrimidinecarboxamide
MF: C₁₈H₁₇Cl₂F₃N₄O₂
FW: 449.3
Purity: ≥98%
UV/Vis.: λ_{max}: 280 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GW 842166X is supplied as a crystalline solid. A stock solution may be made by dissolving the GW 842166X in the solvent of choice, which should be purged with an inert gas. GW 842166X is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of GW 842166X in these solvents is approximately 0.3, 10, and 20 mg/ml, respectively.

GW 842166X is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, GW 842166X should first be dissolved in DMF and then diluted with the aqueous buffer of choice. GW 842166X has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

GW 842166X is a cannabinoid 2 (CB₂) receptor agonist.¹ It increases intracellular calcium mobilization induced by the CB receptor agonist CP 55,940 (Item No. 13241) in HEK cells co-expressing a chimeric Gα_{q/05} protein and the human CB₂ receptor (EC₅₀ = 7.78 μM).² GW 842166X is selective for CB₂ over the CB₁ receptor (IC₅₀s = 0.133 and >25 μM, respectively). It inhibits LPS-induced production of inducible nitric oxide synthase (iNOS), as well as reduces LPS-induced phosphorylation of ERK1/2 in BV-2 microglia cells when used at a concentration of 100 nM.³ GW 842166X inhibits hyperalgesia in a rat model of inflammatory pain induced by complete Freund's adjuvant (ED₅₀ = 0.1 mg/kg).¹

References

1. Giblin, G.M.P., O'Shaughnessy, C.T., Naylor, A., *et al.* Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)-5-pyrimidinecarboxamide, a selective CB₂ receptor agonist for the treatment of inflammatory pain. *J. Med. Chem.* **50(11)**, 2597-2600 (2007).
2. Yao, B.B., Hsieh, G.C., Frost, J.M., *et al.* *In vitro* and *in vivo* characterization of A-796260: A selective cannabinoid CB₂ receptor agonist exhibiting analgesic activity in rodent pain models. *Br. J. Pharmacol.* **153(2)**, 390-401 (2008).
3. Ribeiro, R., Wen, J., Li, S., *et al.* Involvement of ERK1/2, cPLA₂ and NF-κB in microglia suppression by cannabinoid receptor agonists and antagonists. *Prostaglandins Other Lipid Mediat.* **100-101**, (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/26/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM